Results
1 -
10 of
94Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC), Cancer Chemotherapy and Pharmacology Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia, International Journal of Hematology Salvage therapy with single agent bendamustine for recurrent glioblastoma, Journal of Neuro-Oncology Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial, Journal of Neuro-Oncology Investigations on the stability of bendamustin, a cytostatic agent of the nitrogen mustard type, I. Synthesis, isolation, and characterization of reference substances, Monatshefte f??r Chemie / Chemical Monthly Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours, Journal of Cancer Research and Clinical Oncology Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck, Strahlentherapie und Onkologie Temsirolimus acts as additive with bendamustine in aggressive lymphoma, Annals of Hematology First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis, Annals of Hematology Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia, Annals of Hematology